Back to discover
Disease

blast phase chronic myelogenous leukemia, BCR-ABL1 positive

Late-stage therapeutic development
Also known as blast crisis, blast phase CML, blast phase chronic granulocytic leukaemia, blast phase chronic granulocytic leukemia+22 more

blast crisis, blast phase CML, blast phase chronic granulocytic leukaemia, blast phase chronic granulocytic leukemia, blast phase chronic myelocytic leukaemia, blast phase chronic myelocytic leukemia, blast phase chronic myelogenous leukaemia, blast phase chronic myelogenous leukemia, blast phase chronic myeloid leukaemia, blast phase chronic myeloid leukemia, blastic phase CML, blastic phase chronic granulocytic leukaemia, blastic phase chronic granulocytic leukemia, blastic phase chronic myelocytic leukaemia, blastic phase chronic myelocytic leukemia, blastic phase chronic myelogenous leukaemia, blastic phase chronic myelogenous leukemia, blastic phase chronic myeloid leukaemia, blastic phase chronic myeloid leukemia, blast crises, blast phase, blast phases, crises, blast, crisis, blast, phase, blast, phases, blast.

16
Clinical trials
2
Associated genes
2
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Clinical Milestones7View
Results expected 5
Recently completed 1
Activity timeline7

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Nilotinibapproved

Approval — Nilotinib Accord is indicated for the treatment of: - adult and paediatric patients with… (2024)

Bosutinibapproved

Approval — Bosulif is indicated for the treatment of:• Adult and paediatric patients aged 6 years an… (2013)

Dasatinibapproved

Approval — Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Phil… (2006)

Clinical trials

4 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
16
All trials
6
Active
1
Late-stage
6
Completed
Recruiting

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML

Phase 2 · Recruiting · M.D. Anderson Cancer Center

Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Phase 2 · Recruiting · M.D. Anderson Cancer Center

Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms

Phase 2 · Recruiting · M.D. Anderson Cancer Center

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy

Phase 1 · Recruiting · M.D. Anderson Cancer Center
Recently completed

A Phase II Study of the Combination of Decitabine, Venetoclax, and Ponatinib in Patients With Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia

Phase 2 · Completed · M.D. Anderson Cancer Center

Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Phase 2 · Completed · M.D. Anderson Cancer Center

A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase

Phase 1/2 · Completed · M.D. Anderson Cancer Center

Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)

Phase 2/3 · Completed · M.D. Anderson Cancer Center

Donor Lymphocyte Infusion for the Treatment of Malignancy After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multi-center Trial

Phase 1/2 · Completed · Fred Hutchinson Cancer Center

A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial

Phase 2 · Completed · Fred Hutchinson Cancer Center

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApproval — Nilotinib· Nilotinib Accord is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, - adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, - paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. source ↗
2013emaApproval — Bosutinib· Bosulif is indicated for the treatment of:• Adult and paediatric patients aged 6 years and older with newly-diagnosed (ND) chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).• Adult and paediatric patients aged 6 years and older with CP Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.• Adult patients with accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. source ↗
2007emaApproval — Nilotinib· Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib. Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. source ↗
2006emaApproval — Dasatinib· Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy. Sprycel is indicated for the treatment of adult patients with: newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase; chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate; Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

2 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

ABL10.62BCR0.62

Disease biology

2 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Tyrosine-protein kinase ABL1via ABL10.62Breakpoint cluster region proteinvia BCR0.62

Reference

Authoritative identity, definition & identifiers.

Synonyms

blast crisis, blast phase CML, blast phase chronic granulocytic leukaemia, blast phase chronic granulocytic leukemia, blast phase chronic myelocytic leukaemia, blast phase chronic myelocytic leukemia, blast phase chronic myelogenous leukaemia, blast phase chronic myelogenous leukemia, blast phase chronic myeloid leukaemia, blast phase chronic myeloid leukemia, blastic phase CML, blastic phase chronic granulocytic leukaemia, blastic phase chronic granulocytic leukemia, blastic phase chronic myelocytic leukaemia, blastic phase chronic myelocytic leukemia, blastic phase chronic myelogenous leukaemia, blastic phase chronic myelogenous leukemia, blastic phase chronic myeloid leukaemia, blastic phase chronic myeloid leukemia, blast crises, blast phase, blast phases, crises, blast, crisis, blast, phase, blast, phases, blast

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.